Search

Your search keyword '"Nuerxiati, Abulimiti"' showing total 12 results
Start Over Author "Nuerxiati, Abulimiti"
12 results on '"Nuerxiati, Abulimiti"'

4. Independent effect of postoperative neutrophil-to-lymphocyte ratio on the survival of pancreatic ductal adenocarcinoma with open distal pancreatosplenectomy and its nomogram-based prediction

Author

Pu, Ning, primary, Yin, Hanlin, additional, Zhao, Guochao, additional, Nuerxiati, Abulimiti, additional, Wang, Dansong, additional, Xu, Xuefeng, additional, Kuang, Tiantao, additional, Jin, Dayong, additional, Lou, Wenhui, additional, and Wu, Wenchuan, additional

Published
2019
Full Text
View/download PDF

7. AB069. P041. A nomogram based on postoperative neutrophil-to-lymphocyte rate and TNM stage to predict the prognostic value in pancreatic ductal adenocarcinoma with open distal pancreatosplenectomy

Author

Pu, Ning, primary, Yin, Hanlin, additional, Li, Jian-ang, additional, Zhao, Guochao, additional, Xu, Yadong, additional, Nuerxiati, Abulimiti, additional, Wang, Dansong, additional, Xu, Xuefeng, additional, Kuang, Tiantao, additional, Jin, Dayong, additional, Lou, Wenhui, additional, and Wu, Wenchuan, additional

Published
2018
Full Text
View/download PDF

8. Comparison of prognostic prediction between nomogram based on lymph node ratio and AJCC 8th staging system for patients with resected pancreatic head carcinoma: a SEER analysis

Author

Pu, Ning, primary, Li, Jianang, additional, Xu, Yaolin, additional, Lee, Wanling, additional, Fang, Yuan, additional, Han, Xu, additional, Zhao, Guochao, additional, Zhang, Lei, additional, Nuerxiati, Abulimiti, additional, Yin, Hanlin, additional, Wu, Wenchuan, additional, and Lou, Wenhui, additional

Published
2018
Full Text
View/download PDF

11. Alkaline Phosphatase-To-Albumin Ratio as a Prognostic Indicator in Pancreatic Ductal Adenocarcinoma after Curative Resection

Author

Pu, Ning, primary, Gao, Shanshan, additional, Xu, Yadong, additional, Zhao, Guochao, additional, Lv, Yang, additional, Nuerxiati, Abulimiti, additional, Li, Jian-ang, additional, Wang, Dansong, additional, Xu, Xuefeng, additional, Kuang, Tiantao, additional, Wang, Xiaolin, additional, Lou, Wenhui, additional, Liu, Lingxiao, additional, and Wu, Wenchuan, additional

Published
2017
Full Text
View/download PDF

12. Neutralizing TGF-β promotes anti-tumor immunity of dendritic cells against pancreatic cancer by regulating T lymphocytes.

Author

NING PU, GUOCHAO ZHAO, SHANSHAN GAO, YUTONG CUI, YADONG XU, YANG LV, NUERXIATI, ABULIMITI, and WENCHUAN WU

Subjects
*DENDRITIC cells, *ANTINEOPLASTIC agents, *PANCREATIC cancer
Abstract

Previous fundamental or clinical trials of dendritic cell (DC) vaccine against pancreatic ductal adenocarcinoma (PDAC) revealed the burgeoning neoadjuvant immunotherapy. Microarray studies indicated that multiple ingredients of the transfer growth factor beta (TGF-β) pathway were overexpressed in PDAC, which inhibited the intratumoral immune response. To explore whether the DC volume in tumor microenvironment contributes to the differentiation of T cell cohort and test the hypothesis that combining DC vaccine with TGF-β inhibitors will elevate the anti-tumor immune response, we managed to co-culture T cells in vitro with pancreatic cancer cells and DCs in different concentrations, and combine TGF-β blockage with DC vaccine therapy in a murine model of pancreatic cancer. In in vitro studies, we discovered that CD8+ T cytotoxic cell (Tc) presented a significant advantage and lower volume of CD4+ Thelper cell (Th) existed with a certain elevated DC concentration (p < 0.05), associated with declined interleukin (IL)-10 and increased interferon (IFN)-y, which suggested with the DC volume increasing, the enhancing immune effect may represent a great advantage in such a system (p < 0.05). When interfered with anti-TGF-β antibody or TGF-β cytokine, respectively, in the co-culture system, we found IFN-γ producing was extremely higher and Tcell apoptosis relatively descent with TGF-β blockage (p < 0.05). The murine PDAC model demonstrated a survival advantage treated with anti-TGF-β antibody combined with DC vaccine when compared with monotherapy controls (p < 0.05). Therefore, these findings indicated that, through neutralizing TGF-β associated with DC vaccine, the anti-tumor immunity is highly elevated and this combinational therapy will provide an efficacious prospect. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results